Aliases & Classifications for Substance Abuse

Aliases & Descriptions for Substance Abuse:

Name: Substance Abuse 12 29 3 14
Substance-Related Disorders 42 69
Substance Abuse Problem 69

Classifications:



External Ids:

Disease Ontology 12 DOID:302
MeSH 42 D019966
NCIt 47 C16522
SNOMED-CT 64 26416006
UMLS 69 C0013146

Summaries for Substance Abuse

Disease Ontology : 12 A substance-related disorder that involves a maladaptive pattern of substance use leading to significant impairment in functioning.

MalaCards based summary : Substance Abuse, also known as substance-related disorders, is related to multiple personality disorder and personality disorder, and has symptoms including symptoms An important gene associated with Substance Abuse is TF (Transferrin), and among its related pathways/superpathways are Peptide ligand-binding receptors and Beta-Adrenergic Signaling. The drugs Guaifenesin and Methadone have been mentioned in the context of this disorder. Affiliated tissues include testes, brain and liver, and related phenotypes are behavior/neurological and homeostasis/metabolism

CDC : 3 Data are for the U.S.

Wikipedia : 71 Substance abuse, also known as drug abuse, is a patterned use of a drug in which the user consumes the... more...

Related Diseases for Substance Abuse

Diseases related to Substance Abuse via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 127)
id Related Disease Score Top Affiliating Genes
1 multiple personality disorder 31.5 BDNF HTR1B MAOA SLC6A4
2 personality disorder 30.2 BDNF CYP2D6 DRD2 DRD3 DRD4 MAOA
3 hepatitis d 29.0 BDNF CYP2D6 DRD2 DRD4 MAOA NPY
4 schizophrenia 28.5 BDNF CYP2D6 DBH DRD2 DRD3 DRD4
5 eating disorder 11.3
6 alcohol abuse 11.2
7 cocaine abuse 11.1
8 cannabis abuse 11.1
9 opioid abuse 11.1
10 barbiturate abuse 10.8
11 panic disorder 10.8
12 antidepressant type abuse 10.8
13 hallucinogen abuse 10.8
14 phencyclidine abuse 10.8
15 amphetamine abuse 10.8
16 impulse control disorder 10.8
17 withdrawal disorder 10.8
18 sphenoorbital meningioma 10.3 DRD2 DRD3 DRD4
19 intracranial aneurysm 10.3 DRD2 DRD3 DRD4
20 c8 deficiency, type ii 10.3 DRD2 DRD3 DRD4
21 intracranial cavernous angioma 10.3 DRD2 SLC6A3 SLC6A4
22 splenic abscess 10.3 DRD2 SLC6A3 SLC6A4
23 18p deletion syndrome 10.3 DRD2 DRD4 SLC6A3
24 intrahepatic gall duct cancer 10.2 BDNF MAOA SLC6A4
25 anodontia 10.2 HTR1B SLC6A3 SLC6A4
26 hypoglycemic coma 10.2 BDNF MAOA SLC6A4
27 antisocial personality disorder 10.2
28 hypoglycemia 10.2 BDNF DRD2 DRD3 SLC6A4
29 scoliosis 10.2 DBH DRD2 SLC6A3
30 schizoid personality disorder 10.2 DRD3 SLC6A4
31 postencephalitic parkinson disease 10.2 BDNF DRD2 MAOA SLC6A4
32 mastitis 10.2 DRD4 PRL SLC6A3
33 interstitial emphysema 10.2 DBH DRD2 SLC6A4
34 usher syndrome 10.2 DRD2 DRD3 SLC6A3
35 strongyloidiasis 10.2 DRD2 MAOA SLC6A3 SLC6A4
36 ornithosis 10.2 DRD2 MAOA PRL SLC6A4
37 alzheimer disease 17 10.2 DRD3 DRD4 PRL SLC6A4
38 teratoma with malignant transformation 10.2 BDNF CYP2D6 DRD2 DRD3
39 chronic eosinophilic pneumonia 10.2 BDNF MAOA PRL SLC6A4
40 ischemic neuropathy 10.2 CYP2D6 DRD2 DRD3
41 chagas disease 10.2 BDNF HTR1B NPY SLC6A4
42 carcinoma of esophagus, salivary gland type 10.2 CYP2C19 CYP2D6
43 keratosis 10.1 BDNF CYP2D6 MAOA SLC6A4
44 renpenning syndrome 10.1 DBH HTR1B MAOA SLC6A4
45 hemolytic anemia, cd59-mediated, with or without immune-mediated polyneuropathy 10.1 BDNF NPY PRL SLC6A4
46 cavernous hemangioma 10.1 DRD2 DRD3 SLC6A3
47 hepatitis b reinfection following liver transplantation 10.1 CYP2D6 MAOA SLC6A4
48 brain glioblastoma multiforme 10.1 BDNF DRD2 DRD3 SLC6A3 SLC6A4
49 cholesteatoma 10.1 BDNF DRD2 NPY SLC6A3 SLC6A4
50 autism 19 10.1 DBH DRD2 SLC6A3

Graphical network of the top 20 diseases related to Substance Abuse:



Diseases related to Substance Abuse

Symptoms & Phenotypes for Substance Abuse

UMLS symptoms related to Substance Abuse:


symptoms

MGI Mouse Phenotypes related to Substance Abuse:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.19 GABRA2 HTR1B MAG MAOA MOBP NPY
2 homeostasis/metabolism MP:0005376 10.03 DRD2 DRD3 DRD4 GABRA2 MAG MAOA
3 integument MP:0010771 9.56 BDNF DBH DRD2 GABRA2 PRL SLC6A3
4 nervous system MP:0003631 9.53 BDNF DBH DRD2 DRD3 DRD4 DRD5

Drugs & Therapeutics for Substance Abuse

Drugs for Substance Abuse (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 689)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Guaifenesin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 93-14-1 3516
2
Methadone Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 76-99-3 4095
3
Varenicline Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 249296-44-4 5310966
4
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 129722-12-9 60795
5
Amphetamine Approved, Illicit Phase 4,Phase 2,Phase 3,Phase 1 300-62-9 5826 3007
6
Heroin Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 561-27-3 5462328
7
Naloxone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 465-65-6 5284596
8
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 52485-79-7 40400 644073
9
Bupropion Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 34841-39-9, 34911-55-2 444
10
Nicotine Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 54-11-5 942 89594
11
Biperiden Approved Phase 4,Phase 2,Phase 3 514-65-8 2381
12
Cocaine Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-36-2 5760 446220
13
Dopamine Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
14
Methylphenidate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 113-45-1 4158
15
Trazodone Approved, Investigational Phase 4,Phase 3,Phase 2 19794-93-5 5533
16
Acamprosate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 77337-76-9 71158
17
Ethanol Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 64-17-5 702
18
Topiramate Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 97240-79-4 5284627
19
Disulfiram Approved Phase 4,Phase 2,Phase 1 97-77-8 3117
20
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 16590-41-3 5360515
21
Acetylcysteine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 616-91-1 12035
22
Lidocaine Approved, Vet_approved Phase 4,Phase 2 137-58-6 3676
23
Ondansetron Approved Phase 4,Phase 3,Phase 2,Phase 1 99614-02-5 4595
24
Fluoxetine Approved, Vet_approved Phase 4,Phase 3,Phase 2 54910-89-3 3386
25
Clonidine Approved Phase 4,Phase 3,Phase 2,Phase 1 4205-90-7 2803
26
Morphine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 57-27-2 5288826
27
Lamotrigine Approved, Investigational Phase 4,Phase 3,Phase 2 84057-84-1 3878
28
Losartan Approved Phase 4 114798-26-4 3961
29
Oxycodone Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 76-42-6 5284603
30
Methamphetamine Approved, Illicit Phase 4,Phase 2,Phase 3,Phase 1 537-46-2 10836
31
Risperidone Approved, Investigational Phase 4,Phase 2,Phase 1 106266-06-2 5073
32
Valproic Acid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 99-66-1 3121
33
Acetaminophen Approved Phase 4,Phase 3,Phase 2,Phase 1 103-90-2 1983
34
Carbon monoxide Approved Phase 4,Phase 3,Phase 2,Phase 1 630-08-0 281
35
Prazosin Approved Phase 4,Phase 3,Phase 2,Phase 1 19216-56-9 4893
36
Baclofen Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 1134-47-0 2284
37
Citalopram Approved Phase 4,Phase 2,Phase 3,Phase 1 59729-33-8 2771
38
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2 75614-87-8, 51-45-6 774
39
Pentoxifylline Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 6493-05-6 4740
40
Diazepam Approved, Illicit, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 439-14-5 3016
41
Oxytocin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-56-6 439302 53477758
42
Gabapentin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 60142-96-3 3446
43
Lenograstim Approved Phase 4,Phase 3 135968-09-1
44
Menthol Approved Phase 4,Phase 2,Phase 1 2216-51-5 16666
45
Propranolol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 525-66-6 4946
46
Midazolam Approved, Illicit Phase 4,Phase 1,Phase 2 59467-70-8 4192
47
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 1 2078-54-8 4943
48
Desipramine Approved Phase 4,Phase 3,Phase 2 50-47-5 2995
49
Carbamazepine Approved, Investigational Phase 4,Phase 2 298-46-4 2554
50
Amantadine Approved Phase 4,Phase 2,Phase 1 768-94-5 2130

Interventional clinical trials:

(show top 50) (show all 3552)
id Name Status NCT ID Phase
1 Smoking Cessation Treatment for Methadone Maintenance Patients Unknown status NCT01027754 Phase 4
2 Improving Outcomes in Psychosis Associated With Substance Use Using Aripiprazole Unknown status NCT01155544 Phase 4
3 Cognitive Correlates of Substance Abuse, Part 2 - 16 Unknown status NCT00000351 Phase 4
4 Cognitive Correlates of Substance Abuse - 11 Unknown status NCT00000346 Phase 4
5 Nasal Naloxone for Narcotic Overdose Unknown status NCT01912573 Phase 4
6 Buprenorphine and Integrated HIV Care Evaluation Unknown status NCT00124358 Phase 4
7 Improving Substance Use and Clinical Outcomes in Heavy Cannabis Users With Quetiapine Unknown status NCT01153490 Phase 4
8 Comparative Effectiveness of Post-Discharge Strategies for Hospitalized Smokers Unknown status NCT01714323 Phase 4
9 Effectiveness of an E-mail Tracking Intervention Among the Continued Abstinence of Tobacco Consumption Unknown status NCT01494246 Phase 4
10 tDCS as Add on Therapy for Treatment of Tobacco Dependence by Standardized Behaviour Therapy Unknown status NCT01729507 Phase 4
11 Menstrual Cycle Effects on Smoking Cessation and Cue Reactivity Unknown status NCT00664755 Phase 4
12 Efficacy of Caffeine, With and Without Biperiden, as a Maintenance Treatment for Cocaine Dependence Unknown status NCT00495183 Phase 4
13 Impact of Attention Deficit/Hyperactivity Disorder and Substance Use Disorder on Motorcycle Traffic Accidents Unknown status NCT00536419 Phase 4
14 Comparison of Quetiapine and Trazodone Treatment for Insomnia in Dually Diagnosed Veterans Unknown status NCT01662297 Phase 4
15 Safety of Acamprosate for Alcohol Dependence in the Elderly: An Open-Label Study (SAFADIE) Unknown status NCT00655967 Phase 4
16 Topiramate for Hospitalized Patients With Alcoholism: a 12-week Study Unknown status NCT01135602 Phase 4
17 Antabuse in Severe Alcoholism: an Open Controlled Study Unknown status NCT00431262 Phase 4
18 Trial for the Treatment of Alcohol Dependence Unknown status NCT00120601 Phase 4
19 Efficacy of N-Acetyl-Cysteine in Bipolar Disorder and Tobacco Use Disorder Unknown status NCT02252341 Phase 4
20 Acamprosate vs. Placebo in Bipolar Alcoholics Unknown status NCT00466661 Phase 4
21 Effect of Probiotics on Gut-Liver Axis of Alcoholic Hepatitis Unknown status NCT02335632 Phase 4
22 Pharmacologic MRI in Cocaine Addiction Unknown status NCT01652378 Phase 4
23 Fluoxetine and Bupropion to Treat Patients With Depression and Alcoholism Unknown status NCT00449007 Phase 4
24 NAS Treatment - Opiate Versus Non-Opiate Unknown status NCT01734551 Phase 4
25 Transfer From Methadone to Buprenorphine Maintenance Treatment Using Buprenorphine Patches Unknown status NCT00750217 Phase 4
26 Treatment of Alcohol Dependence and Comorbid Bipolar Disorder Unknown status NCT01015586 Phase 4
27 Integrating Buprenorphine Into HIV Treatment Unknown status NCT00241930 Phase 4
28 Prevention of Decompensation in Liver Cirrhosis Unknown status NCT00239096 Phase 4
29 Efficacy and Safety of S-adenosyl-l-methionine in Treatment of Alcoholic Hepatitis With Cholestasis Unknown status NCT02024295 Phase 4
30 Associated Genes With Atomoxetine Response in Attention Deficit Hyperactivity Disorder (ADHD) Unknown status NCT01339286 Phase 4
31 Abuse Liability of Controlled-Release Oxycodone Formulations Completed NCT02101840 Phase 4
32 Pre-Release VIVITROL for Opioid Dependent Inmates Completed NCT01563718 Phase 4
33 Brain Changes in Stimulant Dependent Subjects - 8 Completed NCT00000343 Phase 4
34 Methamphetamine Abuse Treatment in Patients With AIDS - 1 Completed NCT00000321 Phase 4
35 Multimodal Treatment Study of Children With Attention Deficit and Hyperactivity Disorder (MTA) Completed NCT00000388 Phase 4
36 Buprenorphine/Naloxone in the Treatment of Heroin Dependence - 14 Completed NCT00015340 Phase 4
37 Pathophysiological Subtyping of Abnormalities in Cocaine Dependence - 9 Completed NCT00015275 Phase 4
38 Pharmacotherapy and Intensive Treatment - 2 Completed NCT00000218 Phase 4
39 Quetiapine for Cocaine Use and Cravings Completed NCT00232336 Phase 4
40 Methylphenidate Raclopride Positron Emission Tomography (PET) Test - 11 Completed NCT00015301 Phase 4
41 Modeling Impaired Judgement in Cocaine Abusers - 6 Completed NCT00015236 Phase 4
42 Effectiveness of ATMX in Treating Adolescents With ADHD and SUD Completed NCT00218322 Phase 4
43 Facilitating the Adoption of Evidence-Based Depression Management in Substance Use Treatment Programs Completed NCT00137306 Phase 4
44 Treatment of Acute Hepatitis C Virus Infection With Pegylated Interferon in Injection Drug Users Completed NCT00194480 Phase 4
45 Relapse Prevention With Varenicline Completed NCT00944554 Phase 4
46 Substance Dependent Teens - Impact of Treating Depression Study 1 - 1 Completed NCT00061113 Phase 4
47 The Maternal Lifestyle Study (MLS) Completed NCT00059540 Phase 4
48 Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM) Completed NCT00798538 Phase 4
49 Buprenorphine and Integrated HIV Care Completed NCT00317460 Phase 4
50 Paroxetine Treatment in Outpatients With Comorbid PTSD and Substance Dependence Completed NCT00330239 Phase 4

Search NIH Clinical Center for Substance Abuse

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: substance-related disorders

Genetic Tests for Substance Abuse

Genetic tests related to Substance Abuse:

id Genetic test Affiliating Genes
1 Substance Abuse 29

Anatomical Context for Substance Abuse

MalaCards organs/tissues related to Substance Abuse:

39
Testes, Brain, Liver, Monocytes, Kidney, Pituitary, Hypothalamus

Publications for Substance Abuse

Articles related to Substance Abuse:

(show top 50) (show all 694)
id Title Authors Year
1
The impaired anesthesiologist: what you should know about substance abuse. ( 27928715 )
2017
2
Screening, Brief Intervention and Referral to Treatment: implications of SAMHSA's SBIRT initiative for substance abuse policy and practice. ( 28074569 )
2017
3
Challenges in Laboratory Detection of Unusual Substance Abuse: Issues with Magic Mushroom, Peyote Cactus, Khat, and Solvent Abuse. ( 28057187 )
2017
4
Is Kratom the New 'Legal High' on the Block?: The Case of an Emerging Opioid Receptor Agonist with Substance Abuse Potential. ( 28072812 )
2017
5
A Post-Hurricane Katrina Examination of Substance Abuse Treatment Discharges with Co-Occurring Psychiatric and Substance Use Disorders. ( 28045601 )
2017
6
Failure to get into substance abuse treatment. ( 28017185 )
2017
7
Childhood Maltreatment and Unprotected Sex among Female Juvenile Offenders: Evidence of Mediation by Substance Abuse and Psychological Distress. ( 28087129 )
2017
8
Socioeconomic differences in adolescent substance abuse treatment participation and long-term outcomes. ( 28088743 )
2017
9
Interagency collaboration: Strengthening substance abuse resources in child welfare. ( 28064109 )
2017
10
Gender differences in substance abuse, PTSD and intentional self-harm among veterans health administration patients. ( 28013099 )
2017
11
Co-Occurrence of and Recovery from Substance Abuse and Lifespan Victimization: A Qualitative Study of Female Residents in Trauma-Informed Sober Living Homes. ( 28085637 )
2017
12
Childhood sexual abuse and substance abuse: A gender paradox? ( 27912908 )
2017
13
Did you get any help? A post-hoc secondary analysis of a randomized controlled trial of psychoeducation for patients with antisocial personality disorder in outpatient substance abuse treatment programs. ( 28068951 )
2017
14
An efficient genome-wide association test for mixed binary and continuous phenotypes with applications to substance abuse research. ( 27215414 )
2016
15
Advances in Substance Abuse Prevention and Treatment Interventions Among Racial, Ethnic, and Sexual Minority Populations. ( 27159811 )
2016
16
Substance Abuse and Tooth Destruction. ( 27197361 )
2016
17
Interventions for Adolescent Substance Abuse: An Overview of Systematic Reviews. ( 27664597 )
2016
18
An Evaluation of the Ho'ouna Pono Curriculum: A Pilot Study of Culturally Grounded Substance Abuse Prevention for Rural Hawaiian Youth. ( 27180710 )
2016
19
Co-Citation Analysis of Articles Published in Substance Abuse Journals: Intellectual Structure and Research Fields (2001-2012). ( 27588529 )
2016
20
Examination of Life Satisfaction, Child Maltreatment Potential and Substance Use in Mothers Referred for Treatment by Child Protective Services for Child Neglect and Substance Abuse: Implications for Intervention Planning. ( 27617042 )
2016
21
The Relationship of Reflective Functioning to Parent Child Interactions in a Sample of Fathers With Concurrent Intimate Partner Violence Perpetration and Substance Abuse Problems. ( 27158188 )
2016
22
Mental health care in post-genocide Rwanda: evaluation of a program specializing in posttraumatic stress disorder and substance abuse. ( 27610238 )
2016
23
Social Functioning and Self-Esteem of Substance Abuse Patients. ( 27654242 )
2016
24
Evaluating Measures of Fidelity for Substance Abuse Group Treatment With Incarcerated Adolescents. ( 27211991 )
2016
25
The National Acupuncture Detoxification Association protocol, auricular acupuncture to support patients with substance abuse and behavioral health disorders: current perspectives. ( 27994492 )
2016
26
Considering the Contemporary Issues and Unresolved Challenges Facing Therapeutic Communities for Clients with Alcohol and Substance Abuse. ( 27128141 )
2016
27
Prevalence and risk factors of alcohol and substance abuse among motorcycle drivers in Fars province, Iran. ( 27140214 )
2016
28
The use of SBIRT in substance abuse screening. ( 27654089 )
2016
29
Suicide among Young People and Adults in Ireland: Method Characteristics, Toxicological Analysis and Substance Abuse Histories Compared. ( 27898722 )
2016
30
Differences by Gender in Predictors of Motivation Among Substance Abuse Treatment Participants. ( 28001464 )
2016
31
Epistatic interactions involving DRD2, DRD4, and COMT polymorphisms and risk of substance abuse in women with binge-purge eating disturbances. ( 26950642 )
2016
32
Policy on Substance Abuse in Adolescent Patients. ( 27931426 )
2016
33
Vulnerable parenting among mothers with substance abuse in their family of origin: a cross-sectional comparative study of mothers in an infant and toddler program. ( 27652113 )
2016
34
Preventing Substance Abuse With Data-Driven Coalitions. ( 27180417 )
2016
35
Examining Treatment Climate Across Prison-Based Substance Abuse Treatment Groups. ( 27144315 )
2016
36
Probation Staff Attitudes Toward Substance Abuse Treatment and Evidence-Based Practices. ( 27220361 )
2016
37
Substance Abuse Among Blacks Across the Diaspora. ( 27191862 )
2016
38
Hospital care for mental health and substance abuse conditions in Parkinson's disease. ( 27943472 )
2016
39
The behavioral economics of young adult substance abuse. ( 27151545 )
2016
40
A Tool for Assessing a Community's Capacity for Substance Abuse Care. ( 27657505 )
2016
41
Vicarious Trauma and Vicarious Posttraumatic Growth among Substance Abuse Treatment Providers. ( 27163485 )
2016
42
Sexual temptation: substance abuse, no sex, safe sex, risky sex, and STDs. ( 28009539 )
2016
43
Temperament and character profiles associated with depression and treatment response in patients with or without comorbid substance abuse. ( 27565696 )
2016
44
CATHOLIC HOSPITALS ADDRESS SUBSTANCE ABUSE. ( 27120845 )
2016
45
Oxazepam for the Treatment of Substance Abuse and Depression: Is it Appropriate? ( 27135891 )
2016
46
Neurobiology of hedonic tone: the relationship between treatment-resistant depression, attention-deficit hyperactivity disorder, and substance abuse. ( 27601909 )
2016
47
The Contribution of Stress, Cultural Factors, and Sexual Identity on the Substance Abuse, Violence, HIV, and Depression Syndemic Among Hispanic Men. ( 27159650 )
2016
48
Substance Abuse and Trauma. ( 27613348 )
2016
49
The role of mindfulness as approach-based coping in the PTSD-substance abuse cycle. ( 27664564 )
2016
50
Dopamine D4 receptor VNTR polymorphism associated with greater risk for substance abuse among adolescents with disruptive behavior disorders: Preliminary results. ( 26688118 )
2016

Variations for Substance Abuse

Expression for Substance Abuse

Search GEO for disease gene expression data for Substance Abuse.

Pathways for Substance Abuse

Pathways related to Substance Abuse according to GeneCards Suite gene sharing:

(show all 19)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.45 DRD2 DRD3 DRD4 DRD5 GABRA2 HTR1B
2
Show member pathways
12.65 BDNF DRD2 DRD3 DRD4 DRD5
3
Show member pathways
12.58 DRD2 DRD3 DRD4 DRD5 MAOA SLC6A3
4 12.2 DRD2 DRD3 DRD4 DRD5
6
Show member pathways
12.02 BDNF DRD2 DRD5 HTR1B NPY
7 11.87 BDNF MAOA PLP1 SLC6A4 TF
8
Show member pathways
11.85 BDNF DRD2 MAOA SLC6A3
9
Show member pathways
11.77 DRD2 DRD3 DRD4
10 11.7 DBH MAOA TDO2
11
Show member pathways
11.61 DRD2 DRD3 DRD4 DRD5 HTR1B
12 11.41 CYP2C19 CYP2D6 HTR1B MAOA SLC6A4
13
Show member pathways
11.37 CYP2C19 CYP2D6 SLC6A4
14 11.24 CYP2C19 CYP2D6 MAOA
15 11.08 HTR1B MAOA SLC6A4
16
Show member pathways
11.01 MAOA SLC6A3 SLC6A4
17 10.94 DRD2 DRD3 DRD5
18
Show member pathways
10.65 DBH MAOA SLC6A3 SLC6A4 TDO2
19 10.43 MAG PLP1

GO Terms for Substance Abuse

Cellular components related to Substance Abuse according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 integral component of membrane GO:0016021 9.97 CYP2D6 DBH DRD2 DRD3 DRD4 DRD5
2 integral component of plasma membrane GO:0005887 9.23 DRD2 DRD3 DRD4 DRD5 HTR1B MAG
3 endocytic vesicle GO:0030139 9.13 DRD2 DRD3 TF

Biological processes related to Substance Abuse according to GeneCards Suite gene sharing:

(show top 50) (show all 52)
id Name GO ID Score Top Affiliating Genes
1 chemical synaptic transmission GO:0007268 9.97 DBH DRD5 HTR1B NPY PLP1
2 response to drug GO:0042493 9.95 DRD2 DRD3 HTR1B PRL SLC6A3 SLC6A4
3 cellular calcium ion homeostasis GO:0006874 9.88 DRD3 DRD4 DRD5
4 locomotory behavior GO:0007626 9.87 DBH DRD2 DRD3 SLC6A3
5 social behavior GO:0035176 9.83 DRD3 DRD4 SLC6A4
6 visual learning GO:0008542 9.82 DBH DRD2 DRD3
7 neurotransmitter transport GO:0006836 9.82 GABRA2 SLC6A3 SLC6A4
8 feeding behavior GO:0007631 9.81 DRD2 HTR1B NPY
9 negative regulation of blood pressure GO:0045776 9.79 DRD2 DRD3 DRD5
10 associative learning GO:0008306 9.78 DBH DRD2 DRD5
11 negative regulation of adenylate cyclase activity GO:0007194 9.77 DRD2 DRD3 DRD4
12 arachidonic acid secretion GO:0050482 9.76 DRD2 DRD3 DRD4
13 regulation of dopamine secretion GO:0014059 9.73 DRD2 DRD3 HTR1B
14 behavioral response to cocaine GO:0048148 9.72 DRD2 DRD3 DRD4
15 response to ethanol GO:0045471 9.72 DRD2 DRD3 HTR1B PRL SLC6A3
16 response to iron ion GO:0010039 9.71 DRD2 SLC6A3
17 vasoconstriction GO:0042310 9.71 HTR1B SLC6A4
18 negative regulation of cAMP biosynthetic process GO:0030818 9.71 DRD4 HTR1B
19 dopamine receptor signaling pathway GO:0007212 9.71 DRD2 DRD3 DRD4
20 neurotransmitter biosynthetic process GO:0042136 9.7 SLC6A3 SLC6A4
21 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.7 DRD2 HTR1B
22 ammonium transmembrane transport GO:0072488 9.7 SLC6A3 SLC6A4
23 positive regulation of renal sodium excretion GO:0035815 9.7 DRD2 DRD3
24 synaptic transmission, dopaminergic GO:0001963 9.7 DRD2 DRD3 DRD5
25 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.69 DRD2 DRD5
26 negative regulation of voltage-gated calcium channel activity GO:1901386 9.69 DRD2 DRD4
27 behavior GO:0007610 9.69 HTR1B NPY
28 behavioral response to ethanol GO:0048149 9.69 DBH DRD2 DRD4
29 adenylate cyclase-activating dopamine receptor signaling pathway GO:0007191 9.68 DRD3 DRD5
30 regulation of dopamine metabolic process GO:0042053 9.68 DRD4 SLC6A3
31 adenohypophysis development GO:0021984 9.68 DRD2 SLC6A3
32 central nervous system myelination GO:0022010 9.68 MAG PLP1
33 monoamine transport GO:0015844 9.67 SLC6A3 SLC6A4
34 regulation of cAMP metabolic process GO:0030814 9.67 DRD2 DRD3
35 dopamine uptake involved in synaptic transmission GO:0051583 9.67 SLC6A3 SLC6A4
36 dopamine metabolic process GO:0042417 9.67 DRD2 DRD3 DRD4
37 heterocycle metabolic process GO:0046483 9.66 CYP2C19 CYP2D6
38 monoterpenoid metabolic process GO:0016098 9.66 CYP2C19 CYP2D6
39 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.65 DRD2 DRD3
40 fear response GO:0042596 9.63 DBH DRD4
41 negative regulation of dopamine receptor signaling pathway GO:0060160 9.63 DRD2 DRD3
42 prepulse inhibition GO:0060134 9.63 DRD2 DRD3 SLC6A3
43 positive regulation of dopamine uptake involved in synaptic transmission GO:0051586 9.62 DRD2 DRD4
44 acid secretion GO:0046717 9.62 DRD2 DRD3
45 negative regulation of protein secretion GO:0050709 9.61 DRD2 DRD3 DRD4
46 regulation of locomotion involved in locomotory behavior GO:0090325 9.59 DRD2 DRD3
47 G-protein coupled receptor internalization GO:0002031 9.58 DRD2 DRD3 HTR1B
48 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.54 DRD2 DRD3 DRD4
49 dopamine catabolic process GO:0042420 9.43 DBH MAOA SLC6A3
50 response to cocaine GO:0042220 9.35 DRD2 DRD3 DRD5 HTR1B SLC6A3

Molecular functions related to Substance Abuse according to GeneCards Suite gene sharing:

(show all 12)
id Name GO ID Score Top Affiliating Genes
1 G-protein coupled receptor activity GO:0004930 9.97 DRD2 DRD3 DRD4 DRD5 HTR1B NPY
2 signal transducer activity GO:0004871 9.85 DRD2 DRD3 DRD4 DRD5 HTR1B
3 drug binding GO:0008144 9.63 CYP2D6 DRD2 DRD3 DRD4 HTR1B SLC6A3
4 monooxygenase activity GO:0004497 9.58 CYP2C19 CYP2D6 DBH
5 oxygen binding GO:0019825 9.54 CYP2C19 CYP2D6 TDO2
6 neurotransmitter:sodium symporter activity GO:0005328 9.51 SLC6A3 SLC6A4
7 structural constituent of myelin sheath GO:0019911 9.48 MOBP PLP1
8 monoamine transmembrane transporter activity GO:0008504 9.43 SLC6A3 SLC6A4
9 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.43 DRD2 DRD3 DRD4
10 dopamine:sodium symporter activity GO:0005330 9.32 SLC6A3 SLC6A4
11 dopamine neurotransmitter receptor activity GO:0004952 9.26 DRD2 DRD3 DRD4 DRD5
12 dopamine binding GO:0035240 9.02 DRD2 DRD3 DRD4 DRD5 SLC6A3

Sources for Substance Abuse

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27